Mucosal immunization would provide an easy and safe measure in preventing infectious diseases by facilitating mass immunization. In order to represent a promising strategy for mucosal vaccination, oral, nasal, or sublingual immunizations of mice with a recombinant 40-kDa outer membrane protein of Porphyromonas gingivalis (r40k-OMP) and cholera toxin (CT) as a mucosal adjuvant were performed, and mucosal and systemic immune responses were compared. Administration of the antigen via the mucosal routes, such as orally, nasally or sublingually, equally elicited significant levels of r40k-OMP-specific IgG in the serum and high numbers of r40k-OMP-specific antibody-forming cells (AFCs) in the spleen. Nasal and sublingual immunization of mice also induced high levels of mucosal IgA antibodies (Abs) in the saliva and nasal washes compared to oral immunization.
Introduction
Induction of mucosal immune responses is achieved by the deposition of antigen (Ag) via the mucosa (e. g., oral route) but not the systemic route (1) . Furthermore, mucosal immunization has been shown to induce Ag-specific immune responses in both mucosal and systemic compartments (1) (2) (3) . Although systemic vaccination (e. g., intramuscular injection) can induce effective immune responses in the systemic compartment, it does not result in the generation of Ag-specific mucosal immune responses. Considering bacterial infection, mucosal vaccination can offer two layers of immunity (e.g., mucosal and systemic immune response), which can provide an effective barrier against invasion of pathogenic bacteria. It has been shown that delivery of soluble Ag alone is insufficient for the induction of maximum levels of Ag-specific immune responses by the mucosal vaccine. Thus, it is necessary to co-administer it with a mucosal adjuvant for inducing mucosal immune responses including those of the IgA isotype antibody (Ab) (1) (2) (3) .
Cholera toxin (CT), an exotoxin produced by Vibrio cholerae, is the most widely known immunogen and adjuvant for studying mucosal immunity (1) (2) (3) . It is a strong mucosal adjuvant for enhancing of Ag-specific mucosal IgA and systemic IgG responses to mucosally coadministered protein Ag (4, 5) . Previous studies have shown that CT elicits adjuvant responses by inducing Ag-specific Th2-type CD4 + T cells producing IL-4, IL-5, and IL-6, which are responsible for supporting Ag-specific IgA and IgG Ab productions (4, 5) . It has also been shown that CT can modulate a co-stimulatory molecule such as B-7 (6) . For the development of an effective mucosal vaccine, it is essential to consider the use of the adjuvant properties of CT.
Periodontal disease is an inflammatory disease that affects the soft and hard structures that support the teeth. Recent studies have suggested that periodontal disease influences systemic conditions such as cardiovascular disease, diabetes, preterm labor and osteoporosis (7) . Therefore, the prevention of periodontitis by oral care and vaccine development is important for both oral and systemic health.
Porphyromonas gingivalis, a gram-negative anaerobic bacterium, was previously shown to be one of the major pathogens in chronic periodontitis (8) . The bacterial surface components may provide suitable targets for the Ag vaccine. For example, the 40-kDa outer membrane protein of P. gingivalis (40k-OMP) is a key virulence factor for coaggregation (9) and hemagglutination (10) , and is conserved among many strains (11) . Previous studies have shown that IgG Abs induced by the nasal administration of recombinant (r) 40k-OMP with an adjuvant inhibited coaggregation by P. gingivalis (12) . Furthermore, either oral, nasal or sublingual immunization with r40k-OMP prevented alveolar bone loss in response to a P. gingivalis challenge (13, 14, 15) . Therefore, the use of r40k-OMP as a mucosal Ag vaccine may be beneficial in the development of a periodontal vaccine and also for the preventive therapy of systemic diseases. However, we cannot rule out which vaccine administration route is more suitable for prevention of periodontal disease. Therefore, in this study, we evaluated the efficacy of mucosal administration of 40k-OMP produced by P. gingivalis.
Materials and Methods
Mice BALB/c mice were purchased from Sankyo Lab Services (Tokyo, Japan). These mice were maintained under pathogen-free conditions at the experimental facility of the Nihon University School of Dentistry at Matsudo experimental facility. All mice were randomly assigned to control or experimental groups (n=5 per group), and were provided ad libitum access to sterile food and water. They 
Antigen and adjuvant
The recombinant pasmid containing the 40k-OMP gene (pMD125) was kindly provided by Dr. Yoshimitsu Abiko (Nihon University). The r40k-OMP was purified to homoge-neity from a cell suspension of Escherichia coli K-12 harboring pMD 125, as described previously (16) . The purity of the r40k-OMP was determined by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and no contaminating protein bands were noted. Furthermore, an LAL Pyrochrome kit (Associates of Cape Cod, Inc., Woods Hole, MA) was used to determine the level of residual endotoxin. 
Mucosal Immunization and sample collection
Immunization methods were described as follows. For oral immunization, mice were deprived of food for 2 h and then given a solution of sodium bicarbonate to neutralize stomach acidity before oral immunization (17) . Thirty minutes later, these mice were orally immunized by gastric intubation with 250 μl of phosphate-buffered saline (PBS) containing 200 μg of r40k-OMP in presence of 10 μg of CT as a mucosal adjuvant (13) . For sublingual immunization, mice were anesthetized with pentobarbital, and immunized with 30 μl of PBS containing 20 μg of r40k-OMP, and 2 μg of CT was delivered via a micropipette that was applied against the ventral side of the tongue while directed toward the floor of the mouth. Mice were immunized with 7.5 μl of r40k-OMP four times (total volume=30 μl). Ten minute intervals were set between each administration (18) . For nasal immunization, mice were anesthetized with pentobarbital and immunized with a 10 μl aliquot (5 μl per nostril) of PBS containing 10 μg of r40k-OMP with 1 μg of CT (14) . The entire immunization procedure was conducted on days 0, 7, and 14. Serum, saliva, nasal washes and fecal extracts were collected from each group to examine the 40k-OMP-specific Ab responses.
Detection of Ag-specific Ab responses
Ab titers in serum, saliva, nasal washes and fecal extract samples were determined by an enzyme-linked immunosorbent assay (ELISA) (14) . Briefly, plates were coated with the r40k-OMP (5 μg/ml) and blocked with a 1% bovine serum albumin (BSA), and analyses were performed in duplicate. After the plates were blocked, serial dilutions of serum, saliva, nasal washes and fecal extracts were 1:2 8 , 1:2 2 , 1:2 2 and 1:2 2 , respectively. Following incubation, plates were washed and peroxidase-labeled goat anti-mouse γ-or α- 
Measurement of antibody-forming cells
Mononuclear cells from the spleen were isolated aseptically by gentle teasing through stainless steel screens as described elsewhere (19) . Nasal passages (NPs) and
nasopharyngeal-associated lymphoreticular tissue (NALT)
were isolated using a previously described protocol with some modification (19) . Mononuclear cells from the submandibular gland (SMG) were isolated by an enzymatic dissociation procedure with collagenase (0.3 mg/ml; Nitta Gelatin Co. Ltd, Osaka, Japan) followed by a discontinuous
Percoll gradient centrifugation (GE Healthcare UK, Ltd, Little Chalfont, Buckinghamshire, UK) (19) . Mononuclear cells from the Peyerʼs patches (PP) were isolated excising the PP from the small intestineʼs wall. Cells were dissociated with collagenase, described above (17) . Lamina propria (LP) was isolated after removal of the PP and mesenteric lymph nodes from the small intestine. Cells were prepared according to the previously described method (17) . To determine the numbers of 40kDa-OMP-specific Ab-forming cells (AFCs), an enzyme-linked immunospot (ELISPOT) assay was performed as previously described (20 and AFCs were counted with the aid of a stereomicroscope (SZH-ILLLB; Olympus, Tokyo, Japan) (19) .
Statistical analysis
The data are presented as means±standard error (SE).
Differences between the groups were considered significant at P<0.05 using an unpaired Studentʼs t test.
Results

Induction of 40k-OMP-specific antibody responses by mucosal immunization
In our initial experiment, mice were orally, nasally, or As a mucosal adjuvant, CT given via the oral routes induces Th2 cells that secrete high levels of IL-4(4, 25, 26); however, the IL-4 cytokine provides a helper signal for the induction of IgE Abs that may cause anaphylactic reactions (27, 28) . In this regard, previous studies have shown that nasal or sublingual immunization resulted in the induction of both Th1-and Th2-type cytokines in mucosal effector sites such as NP, SMG or submandibular lymph nodes, for the production of Ag-specific S-IgA Abs (15, 29) .
Although nasal immunization has been widely used for mucosal immunization because Ags are not subjected to the degradation usually caused by oral administration, several studies have reported that nasally administered Ags, such as CT and adenovirus vectors, diffuse through the perineural space as a result of retrograde passage through the olfactory epithelium (30, 31) . A clinical study also suggested a strong association between the nasal influenza vaccine and Bellʼs palsy (32) . These findings raise concerns with regard to nasal administration and the potential threat posed by vaccine trafficking in neural tissues, including the central nervous system. In this regard, it has been shown that after sublingual administration, a live or inactivated influenza virus does not migrate into the central nervous system (24) .
Thus, sublingual immunization may be a more promising vaccination route than the nasal route.
In summary, this study has provided evidence that the nasal or sublingual administration of the r40k-OMP together with CT was superior to oral immunization in inducing a 40k-OMP-specific serum IgG as well as salivaly IgA response associated with the increase in the antigen specific AFCs in SMG. These findings further emphasize the importance of the generation of Ag-specific IgA Ab, which possesses the ability to block the bacterial attachment to the epithelial cells. Since there are no significant differences between nasal and sublingual immunization in the titer of serum IgG and salivary IgA, sublingual immunization may be a more suitable method to control P. gingivalis infections.
